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Ethnic origin, genetics, gender and environmental factors have been shown to influence some immunologic indi-
ces, so that development of reference values for populations of different backgrounds may be necessary. We have de-
termined the distribution of lymphocyte subsets in healthy Brazilian individuals from birth to adulthood. Lymphocyte 
subsets were determined using four-colour cytometry in a cross-sectional study of 463 human immunodeficiency 
virus-unexposed children and adults from birth through 49 years of age. Lymphocyte subsets varied according to 
age, as previously observed in other studies. However, total CD4+ T cell numbers were lower than what was de-
scribed in the Pediatric AIDS Clinical Trials Group P1009 (PACTG P1009), which assessed an American population 
of predominantly African and Hispanic backgrounds until the 12-18 year age range, when values were comparable. 
Naïve percentages and absolute values of CD8+ T cells, as assessed by CD45RA expression, were also lower than 
the PACTG P1009 data for all analysed age ranges. CD38 expression on both CD4+ and CD8+ T cells was lower than 
the PACTG P1009 values, with a widening gap between the two studies at older age ranges. Different patterns of cell 
differentiation seem to occur in different settings and may have characteristic expression within each population.
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Peripheral lymphocytes are known to vary in num-
ber and percentage from birth until death. The first stud-
ies on the subject dealt with small sample sizes and a 
limited number of cell subsets were analysed (Yachie et 
al. 1981, Yanase et al. 1986, Wiener et al. 1990, Erkeller-
Yuksel et al. 1992, Calado et al. 1999). The development 
of new laboratory techniques, the discovery of different 
cell subsets and the use of various cell markers have led 
to a constant need to update previous reference values. 
Moreover, different variables have proved to interfere 
with normal ranges of all of these cell subsets.
Ethnic origin, genetics, gender and environmental 
factors have been shown to influence some immunologic 
indices, so that the development of reference values for 
populations of different backgrounds may be necessary 
to improve diagnosis and follow-up of individuals with 
chronic diseases and an altered immune system.
Previous studies have found that exclusively-breastfed 
infants had a higher thymic index than partially-breastfed 
or formula-fed infants as assessed by sonography (Hassel-
balch et al. 1997). Additionally, CD8+ T cell numbers were 
higher among exclusively-breastfed children, who also 
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had a higher thymic index (Jeppensen et al. 2004). The 
authors speculated on the potential for both current and 
long-term immune-modulating effects of human milk on 
the developing immune system (Jeppensen et al. 2004).
Because more intense and frequent modifications 
occur in the developing immune system, the paediatric 
age range is the period of life when more changes are 
observed. Hence, the need for immunologic reference 
values that do vary across the neonatal period, infancy, 
childhood and adolescence is undisputable.
In the present study, we have determined the distri-
bution of lymphocyte subsets in healthy Brazilian neo-
nates, infants, children, adolescents and adults.
SUBJECTS, MATERIALS AND METHODS
Patients and study design - This study was an ob-
servational, cross-sectional assessment of lymphocyte 
subsets in human immunodeficiency virus (HIV)-un-
exposed healthy children from birth to 49 years of age. 
The protocol was approved by the Ethical Committee 
of the Federal University of São Paulo (UNIFESP), in 
São Paulo, Brazil. All individuals or parents - in the case 
of individuals below 18 years of age - gave written in-
formed consent prior to enrolment in the study.
Inclusion criteria were: neonatal weight of 2,500 g 
or more, having no chronic diseases or previous clini-
cal findings suggestive of immune compromise (e.g., 
meningitis, pneumonia, repetitive acute upper respira-
tory infections or diarrhoea), having no acute disease in 
the previous seven days before blood collection, using no 
medication other than vitamins, not being pregnant and 
not being HIV-exposed.
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Age strata were organised as follows: cord blood, one-
91 days old (0-3 months), 92-182 days old (3-6 months), 
183-364 days old (6-12 months), from the first birthday to 
the day before the second birthday (1-2 years), from the 
second birthday to the day before the sixth birthday (2-6 
years), from the sixth birthday to the day before the 12th 
birthday (6-12 years), from the 12th birthday to the day 
before the 19th birthday (12-18 years) and from the 19th 
birthday to the day before the 49th birthday (19-48 years).
For each age strata, effort was made to have an equal 
distribution of male and female subjects.
Data regarding the period of exclusive and non-ex-
clusive breastfeeding were also collected at study entry 
up to the 12-18 year age stratum.
Cord blood collection was performed in two neonatal 
units from hospitals associated with UNIFESP. Individ-
uals from all other age strata were assessed at São Paulo 
Hospital and Centro Assistencial Cruz de Malta, in São 
Paulo. Four hundred and sixty-three subjects participat-
ed in the study, comprising a minimum of 50 individuals 
per age group.
Blood collection - Cord blood (10 mL) was collected 
from the umbilical vein. For all other age strata, a 5-mL 
blood sample of peripheral blood was collected. Samples 
were put into ethylenediamine tetraacetic acid-treated 
vacuum tubes for complete blood counts (CBC) and 
phenotypic analysis of peripheral blood mononuclear 
cell subsets using flow cytometry assays.
CBC - All samples were tested using ADVIA 120 
automatic counter (Bayer HealthCare, Germany). When 
indicated, a slide smear was performed for manual count 
by a trained staff.
Flow cytometry analysis - Cord and peripheral blood 
mononuclear cells were assessed by flow cytometry 
(FACSCalibur, BD Biosciences, USA) within 18 h of 
blood collection and analysed using CellQuest software 
(BD Biosciences). Four-colour phenotypic characterisa-
tions were performed in fresh blood using a lyse-wash 
protocol. Appropriate isotype controls (IgG1-FITC, 
IgG1-PE, IgG1-APC, IgG2a-PE) (BD Biosciences) were 
used to evaluate non-specific staining. For each sample, 
multiparametric data were acquired for 10,000 events.
Cell numbers per cubic millilitre of blood were ob-
tained using the lymphocyte counts from the CBC.
The following monoclonal antibody (MAb) (all 
from BD Biosciences) combinations were used: CD4+ 
T lymphocytes and differentiation subsets using 
CD45RA and CCR7. Using CD3-APC, CD4-PerCP, 
CD45RA-FITC and CCR7-PE, T cell subsets were 
defined as naïve, CD3+CD4+CD45RA+CCR7+, cen-
tral memory, CD3+CD4+CD45RA-CCR7+, effector 
memory, CD3+CD4+CD45RA-CCR7-, and effector, 
CD3+CD4+CD45RA+CCR7- (Maecker et al. 2012).
CD4+ T lymphocytes and differentiation subsets us-
ing CD45RA and CD27 - Using CD3-APC, CD4-PerCP, 
CD45RA-FITC and CD27-PE, T cell subsets were defined 
as naïve, CD3+CD4+CD45RA+CD27+, effector memory, 
CD3+CD4+CD45RA-CD27+ and CD3+CD4+CD45RA-
CD27-, and effector, CD3+CD4+CD45RA+CD27- (Ha-
mann et al. 1997).
CD8+ T lymphocytes were characterised in the same 
way for differentiation subsets by substituting CD4-
PerCP MAb for CD8-PerCP MAb (Hamann et al. 1997, 
Maecker et al. 2012).
Fig. 1: illustrative example of flow cytometry plots for data analysis. Lymphocytes were selected on the side scatter/forward scatter plot with a 
gate as shown in A. T cells were identified from the gate of lymphocytes as CD3+ (B), B cells, as CD3-CD19+ (C) and natural killer (NK) cells, as 
CD3-CD16+/CD56+ (D). CD4+ T cells were identified from the gate of lymphocytes as CD3+CD4+ (E) and then separated in differentiation subsets 
using CD45RA/CCR7 (F) or CD45RA/CD27 markers (G); CD38 and CD25 expression were evaluated on CD4+ T cells in H and I, respectively. 
CD8+ T cells were identified from the gate of lymphocytes as CD3+CD8+ (J) and then separated in differentiation subsets using CD45RA/CCR7 
(K) or CD45RA/CD27 markers (L); CD38 and CD56 expression were evaluated on CD8+ T cells in M and N, respectively. Isotypic controls were 
employed to set the gates in F-I, K-N plots.
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CD4+ T lymphocyte activation - Using CD3-APC, 
CD4-PerCP, CD38-FITC and CD25-PE, CD38 and 
CD25 expression were evaluated as the percentage of 
positive CD3+CD4+ T cells for each marker.
CD8+ T lymphocyte activation - Using CD3-APC, 
CD8-PerCP and CD38-FITC, CD38 expression was eval-
uated as the percentage of positive CD3+CD8+ T cells.
CD8+ T lymphocytes with cytolytic effector function 
- Using CD3-APC, CD8-PerCP and CD56-PE, CD56 ex-
pression was evaluated as the marker associated with cy-
tolytic function (Pittet et al. 2000, Poonia & Pauza 2014).
B lymphocytes - Using CD3-APC and CD19-FITC, B 
lymphocytes were identified as CD3-CD19+ cells.
Natural killer (NK) cells - Using CD3-APC, CD45-
PerCP, CD16-PE and CD56-PE, NK cells were quanti-
fied by the CD45+CD3-CD56+CD16+ phenotype.
Fig. 1 shows an illustrative example of flow cytom-
etry plots used for data analysis.
Statistical analysis - Data were analysed using 
Minitab 15.1 (Minitab, USA) and Stata 7.0 (Stata, USA). 
Percentiles (10th, median and 90th) of end-point distri-
butions are based on percentiles of observed data. Com-
parison with Pediatric AIDS Clinical Trials Group P1009 
(PACTG P1009) data (Shearer et al. 2003) was performed 
by measuring the median 95% confidence intervals for 
each parameter within age strata from zero-three months 
up to 12-18 years and comparing them with median values 
from the corresponding data from Shearer et al. (2003). 
The level of significance was set at p < 0.05.
RESULTS
Four hundred and sixty-three individuals participat-
ed in the study. The characteristics of study subjects are 
summarised in Table I. They reflect the Brazilian pop-
ulation, where the majority of children are exclusively 
breastfed during the first three or four months. After the 
introduction of formula or solid food, many are still par-
tially breastfed during the second semester of life.
Table II presents subset percentages of peripheral 
blood lymphocytes and Table III depicts cell subset counts 
of peripheral blood lymphocytes in different age strata 
from healthy Brazilian children, adolescents and adults.
During the first two years one observes an increase 
in absolute numbers of CD4+ T, CD8+ T and B lympho-
cytes, with a subsequent reduction in numbers from two 
years on for CD4+ T and CD8+ T and from six months 
on for B cells. NK cell numbers, in contrast, show a pro-
gressive decrease from birth and stabilise around the 
two-six year age strata.
With respect to T cell differentiation, there is a pro-
gressive decline in naïve T cells, but to a variable extent 
depending on the cell markers utilised (CD45RA/CCR7, 
CD45RA/CD27 or CD45RA). CD38 expression shows 
a faster decrease in CD8+ T cells than in CD4+ T cells. 
CD25 expression in CD4+ T cells increases only in per-
centage from the two-six year age strata on.
The CD56+ T cell subset percentage is stable up to 
the one-two year strata and increases from then on.
Results from the present study were compared with 
data from PACTG P1009 (Shearer et al. 2003). Parame-
ters compared were those that were tested by both studies 
TABLE I
Demographic data and breastfeeding information of study participants
Cord 
blood
0-3 
months
3-6 
months
6-12 
months
1-2 
years
2-6 
years
6-12 
years
12-18 
years
19-48 
years
Age strata (n) 53 51 50 53 50 55 50 50 51
Feminine gender 
[n (%)]
10 (18.9) 19 (37.2) 27(54) 24 (45) 23 (46) 22 (40) 29 (58) 22 (44) 25 (49)
Exclusive breastfeeding at assessment 
[n (%)]
NA 39 (77) 20 (40) - - - - - NC
Partial breastfeeding at assessment 
[n (%)]
NA 10 (20) 14 (28) - - - - - NC
Total exclusive breastfeeding time 
(mean  ±  SD) (months)
NA - - 3.6 ± 2.7 4.7 ± 2.5 3.5 ± 4.0 4.1 ± 2.9 4.2 ± 2.9 NC
Total breastfeeding time 
(mean  ±  SD) (months)
NA - - 5.4 ± 2.8 8.8 ± 5.7 8.3 ± 9.7 12.7 ± 13.2 9.2 ± 9.5 NC
Children with formula only from birth 
[n (%)]
NA 2 (4) None None 2 (1) 6 (11) 1 (0.5) 5 (10) NC
NA: not applicable; NC: data not collected; SD: standard deviation.
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Fig. 2: total lymphocyte, CD3+ T cell, CD4+ T cell, CD8+ T cell, B cell and natural killer (NK) cell counts in American children and adolescents from 
Pediatric AIDS Clinical Trials Group P1009 (PACTG P1009) study and from Brazilian children and adolescents distributed in similar age strata. 
Data are presented in median values for each age stratum, with 95% confidence interval (CI) shown for the Brazilian cohort. Study data are consid-
ered statistically different if median values from PACTG P1009 study are not included in the 95% CI of the Brazilian cohort. m: months; y: years.
Fig. 3: CD4+ T and CD8+ T cells in American children and adolescents from Pediatric AIDS Clinical Trials Group P1009 (PACTG P1009) study 
and in Brazilian children and adolescents distributed in similar age strata. Cells are analysed according to percentage and absolute values of 
naïve subsets (CD45RA+) and percentage of CD38+ cells. Study data are considered statistically different if median values from PACTG P1009 
study are not included in the 95% confidence interval of the Brazilian cohort. m: months; y: years.
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within age strata from zero-three months to 12-18 years. 
They were: total lymphocyte, CD3+ T cell, CD4+ T cell, 
CD8+ T cell, B cell and NK cell counts (Fig. 2), CD4+ T 
cells and CD8+ T cells were also compared by percent-
age and absolute values of naïve subsets (CD45RA+) and 
percentage of CD38+ cells (Fig. 3).
Brazilian CD4+ T cell numbers were lower than those 
from the PACTG P1009 (Shearer et al. 2003) up to ado-
lescence. Naïve CD4+ and CD8+ T cell percentages were 
also lower in Brazilian children, but percentages were 
comparable to the American study in older children and 
adolescents. CD38 expression on CD4+ and CD8+ T cells, 
in contrast, showed an intense reduction among Brazil-
ian children and adolescents with a progressive differ-
ence when compared to individuals from the PACTG 
P1009 (Shearer et al. 2003).
DISCUSSION
We have assessed the distribution of lymphocyte 
subsets in healthy Brazilian neonates, infants, chil-
dren, adolescents and adults. Individuals were not sep-
arated according to different race-ethnic groups due 
to the very mixed race characteristic of the Brazilian 
population. Demographic data showed a predominantly 
breastfed population with very rare (0-11%) exclusively 
formula-fed children.
Total lymphocyte, CD3+ T cell, CD8+ T cell, B cell 
and NK cell numbers showed similar values in age strata 
as depicted by Shearer et al. (2003) when assessing an 
American population with predominantly African and 
Hispanic backgrounds. CD4+ T cell counts, in contrast, 
were lower than Shearer et al.’s (2003) values up to the 
12-18 year age range when values were then comparable.
Brazilian median cord blood values/mm3 were also 
lower than Ethiopians’ with respect to CD3+ T (1,565 vs. 
2,640), CD4+ T (1,140 vs. 1,816) and CD8+ T cells (433 
vs. 730). In contrast, total lymphocyte (4,260 vs. 3,714), 
B (569 vs. 528) and NK cell numbers (668 vs. 668) were 
comparable to Ethiopians’ (Tsegaye et al. 2003).
When compared with 39 British term infants at 
six-eight weeks of life, our data from the zero-three 
month age range showed low total lymphocytes (5,380 
vs. 5,902), CD3+ T cells (3,411 vs. 4,098), CD4+ T cells 
(2,281 vs. 2,946) and B cells (1,085 vs. 1,481), but similar 
CD8+ T cells (877 vs. 971) and higher NK cells (502 vs. 
277) in the Brazilian cohort (Berrington et al. 2005).
Lugada et al. (2004), studying a Ugandan population, 
found that the decline in CD4+ and CD8+ T cells extend-
ed throughout childhood and adolescence, which is dif-
ferent from other western studies (Shearer et al. 2003).
Other studies performed in African countries have 
noted low CD4+ T cell numbers in comparison to west-
ern countries. That was the case for Sagnia et al. (2011), 
who stratified children from birth to six years in a simi-
lar way as Shearer et al. (2003) and our group. CD4+ T 
cells/mm3 were very close to our median results (cord, 
1,552; 0-3 months, 2001; 3-6 months, 2,133; 6-12 months, 
2,252; 1-2 years, 1,667; 2-6 years, 1,289). Another study 
performed in Malawi also showed low CD4+ T cell num-
bers among children compared to Shearer et al. (2003), 
but similar CD4+ T cell numbers among adults (Mandala 
et al. 2010). In contrast, Abdelltef et al. (2014) evaluated 
a Sudanese population and found that low CD4+ T cells 
were present even in adults.
When CD4+ and CD8+ T cell subsets from our Bra-
zilian group were assessed using CD45RA and CCR7 
markers, naïve cells (CD45RA+CCR7+) were lower for 
all age strata both in percentage and absolute values 
when compared with Shearer et al.’s (2003) data using 
CD45RA and CD62L markers.
We have also studied CD4+ and CD8+ T cell subsets 
using CD45RA and CD27 markers. Naïve cells defined 
as CD45RA+CD27+ showed higher percentages than 
CD45RA+CCR7+ naïve cells.
However, when CD45RA+ naïve cells were compared 
to Shearer et al.’s (2003) data, both percentages and abso-
lute values for CD8+ T cells were lower for all age strata 
that were available for comparison. When CD4+ T cells 
were analysed in the same way, the percentage of naïve 
cells were similar from the two-six year range onwards 
and absolute values were similar to Shearer’s from the 
six-12 year stratum onwards.
The activation marker available for comparison in 
the literature was mainly CD38. Our results showed a 
steady decline in positive cells from birth through adult-
hood, much in accordance with what was found by Mc-
Closkey et al. (1997) and much lower than those reported 
by Shearer et al. (2003) for both CD4+ and CD8+ T cells.
In Thailand, researchers also observed different 
CD38 expression on CD8+ T cells when compared with 
Caucasians; Thai HIV-negative individuals had twice the 
CD38 expression of Caucasians (Sukwit et al. 2005).
Tiba et al. (2011) in Burkina Faso, Africa, noted 
different expression of CD38 on CD8+ T cells among 
healthy individuals. The authors hypothesised that en-
vironmental exposure may influence peripheral blood T 
cell activation. In their study, adults from a rural set-
ting had higher expression of CD38 than those from an 
urban setting. In their opinion, both the expression of 
activation markers and the distribution pattern of T cell 
differentiation subsets may be a surrogate parameter for 
environmentally-driven immune senescence.
The peculiar CD38 expression in the Brazilian co-
hort was probably the most striking of our results, be-
cause lower levels persisted until adulthood in compari-
son with Shearer et al. (2003). CD38 is a multifunctional 
ectoenzyme that uses nicotinamide adenine dinucleotide 
(NAD) as a substrate to generate second messengers. 
It was identified as one of the main cellular NADases 
in mammalian tissues and appears to regulate cellular 
levels of NAD in multiple tissues and cells. NAD par-
ticipates in multiple physiological processes, such as in-
sulin secretion, control of energy metabolism, neuronal 
and cardiac cell survival, airway constriction, asthma, 
aging and longevity (Chini 2009). CD38 is a powerful 
disease marker for human leukaemias and myelomas, 
is directly involved in the pathogenesis and outcome of 
chronic lymphocytic leukaemia (Malavasi et al. 2008) 
and is a marker of immune activation in HIV infection 
(Zaccarelli-Filho et al. 2007).
In line with the influence of dietary habits on the 
development of the immune system, formula-fed infants 
evaluated at the age of four months had higher absolute 
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counts of CD4+ CD38+ T cells than breastfed infants (Po-
zo-Rubio et al. 2013). The fact that lower CD4+ CD38+ T 
cell counts were found in breastfed children supports the 
enhancing effect of breastfeeding on lymphocyte matu-
ration and may explain the low CD38 expression on T 
cells from Brazilian children.
The other possible concern refers to CD4+ T cell val-
ues: they were statistically lower than Shearer et al.’s 
(2003) up to the six-12 year age range. This finding may 
lead to a misclassification of Brazilian children as immu-
nocompromised if the Centers for Disease Control and 
Prevention, Division of Pediatric Human Immunodefi-
ciency Virus classification is used. Indeed, some individ-
uals within the three-six months, six-12 months, one-two 
years and two-six years age ranges would be classified 
as “evidence of moderate suppression” (category 2) if we 
consider the 1994 revised classification system for HIV 
infection in children less than 13 years of age based on 
CD4+ T cell numbers (CDC 1994). However, even Shear-
er et al.’s absolute values would have some children in the 
two-six year age range classified as “evidence of moder-
ate suppression” (category 2) if the same Pediatric HIV 
classification from CDC (1994) was employed.
Interestingly, older age strata tend to vary less 
among different studies. These findings suggest that 
the immune system matures in different patterns in di-
verse populations, probably due to diverse genetic back-
grounds, but also due to varied antigenic stimuli dur-
ing infancy and childhood. This is especially relevant 
currently as the environmental influence is noted on 
the differentiation of the immune system (Sommer & 
Bäckhed 2013). Unfortunately, not all studies subdivide 
samples into similar age ranges, which makes compari-
sons between studies more difficult.
Moreover, cells are assessed in varied ways, for in-
stance, with respect to differentiation, increasing the 
problem of comparison between studies. Standardising 
immunophenotyping is the first step to allow a com-
parison between results from different research groups 
(Maecker et al. 2012). However, in an effort to better 
understand the immune system, one needs to establish 
what the limits between health and disease are in differ-
ent settings and age strata.
In summary, our results are consistent with previ-
ous reports suggesting that various lymphocyte subsets 
show similarities across different populations, but dif-
ferent patterns of cell populations are also present. CD4+ 
T cell counts are probably the most frequently reported 
divergent parameter.
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